Complete pathological response of colorectal peritoneal metastases in Lynch syndrome after immunotherapy case report: is a paradigm shift in cytoreductive surgery needed?

[1]  I. Nagtegaal,et al.  How to measure tumour response in rectal cancer? An explanation of discrepancies and suggestions for improvement. , 2020, Cancer treatment reviews.

[2]  M. Rugge,et al.  Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status , 2019, Journal of Immunotherapy for Cancer.

[3]  J. Madore,et al.  Targeting CD39 in cancer reveals an extracellular ATP and inflammasome driven tumor immunity. , 2019, Cancer discovery.

[4]  M. Price,et al.  Meta‐analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy , 2019, BJS open.

[5]  D M Parkin,et al.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods , 2018, International journal of cancer.

[6]  S. Roka,et al.  Mutations of RAS/RAF Proto-oncogenes Impair Survival After Cytoreductive Surgery and HIPEC for Peritoneal Metastasis of Colorectal Origin , 2018, Annals of surgery.

[7]  V. Velculescu,et al.  Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  M. Pocard,et al.  A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. , 2018, Journal of Clinical Oncology.

[9]  C. Boland,et al.  Recent progress in Lynch syndrome and other familial colorectal cancer syndromes , 2018, CA: a cancer journal for clinicians.

[10]  H. Mukae,et al.  Successful treatment with nivolumab for lung cancer with low expression of PD‐L1 and prominent tumor‐infiltrating B cells and immunoglobulin G , 2018, Thoracic cancer.

[11]  Publisher's Note , 2018, Anaesthesia.

[12]  B. Kc,et al.  Advances in Immunotherapy in the Treatment of Colorectal Cancer , 2017 .

[13]  J. Desai,et al.  Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142. , 2017 .

[14]  S. Laurberg,et al.  Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines , 2017, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[15]  Hajime Uno,et al.  Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Tournigand,et al.  Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. , 2016, The Lancet. Oncology.

[17]  J Ricke,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  F. Quintana,et al.  Regulation of the T Cell Response by CD39. , 2016, Trends in immunology.

[19]  G. Freeman,et al.  A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2 , 2015, Clinical Cancer Research.

[20]  A. Ghazalpour,et al.  Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[21]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[22]  D. Sargent,et al.  Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Labianca,et al.  Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  F. Sinicrope.  DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer , 2010, Nature Reviews Clinical Oncology.

[25]  M. Bertagnolli,et al.  Molecular origins of cancer: Molecular basis of colorectal cancer. , 2009, The New England journal of medicine.

[26]  M. Ligtenberg,et al.  Deficient mismatch repair system in patients with sporadic advanced colorectal cancer , 2009, British Journal of Cancer.

[27]  M. Kloor,et al.  Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. , 2008, Gastroenterology.

[28]  P. Modrich.  Mechanisms in Eukaryotic Mismatch Repair* , 2006, Journal of Biological Chemistry.

[29]  J. Issa.  CpG island methylator phenotype in cancer , 2004, Nature Reviews Cancer.

[30]  A. Duval,et al.  Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. , 2002, Cancer research.

[31]  E. Buchbinder,et al.  CTLA-4 and PD-1 Pathways , 2016, American Journal of Clinical Oncology.

[32]  K. Kinzler,et al.  The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints , 2015, Journal of Immunotherapy for Cancer.

[33]  O. Dworak,et al.  Pathological features of rectal cancer after preoperative radiochemotherapy , 1997, International Journal of Colorectal Disease.